Provider review
Rewinding RX review
By Derek Olsson ·
Its own homepage claims 'never a nurse,' then its own FAQ lists nurse practitioners
Semaglutide is $119 a month and tirzepatide $169, flat, with a refund if you are not approved. Its homepage hero promises "never a physician assistant or nurse" while the FAQ on that same page lists nurse practitioners in the network.
Straight talk: how we earn — some, not all, of these are affiliate links; start a program through one and we may earn a commission at no extra cost to you. Straight about the rest, too: the write-ups say what each provider is actually worth, and a commission does not change a word of them. Full disclosure here.
On this page
The verdict
Rewinding RX publishes real, flat GLP-1 pricing and backs it with a LegitScript seal, but its own homepage claims cases are 'never' reviewed by a nurse while its own FAQ on the same page lists nurse practitioners as part of its clinical network — a direct, self-contradicting claim about who actually reviews your case.
Rewinding RX isn't on any of our comparisons yet. The providers we compare in this category are on our semaglutide provider ranking. Nothing on this page is a performance claim — see how semaglutide works for what the treatment does and does not do.
Alternatives to Rewinding RX
Other providers we work with. Compare prices before you sign up anywhere.
CoreAge RxPartner
From $79/mo; selected price dose-flat
Direct MedsPartner
$297/30 days; 90-day shipment
Received an FDA warning letter in September 2025 — see the FDA’s warning-letter database.
SHEDPartner
From $199 per advertised month
Who it is for, and who it is not
A good fit if
- You want flat, published monthly pricing for microdose-style GLP-1 therapy
- You want a provider that displays a LegitScript seal
- You're interested in a broader longevity/biological-age framing alongside GLP-1 prescribing
Look elsewhere if
- You're specifically choosing this provider because it claims cases are reviewed only by an MD, never a nurse — its own FAQ contradicts that on the same page
- You want a consistent legal entity name — its About page and footer disagree (LLC vs. Ltd)
- You want a physical corporate address disclosed — none was found anywhere on the site
What it actually costs
What they advertise
Tirzepatide (microdosing) $169/month, semaglutide $119/month — flat monthly rates, no lock-in, full refund if not approved.
What you actually pay, month to month
$119/month (semaglutide) or $169/month (tirzepatide), flat regardless of dose.
The commitment trap
The $169 and $119 figures are two separate drugs (tirzepatide and semaglutide), not a discount relationship between a headline price and a real one.
Prices come from Rewinding RX's own website and can change without notice — confirm before you buy. Work out what a vial actually gives you with our peptide dose calculator.
What is included
Compare the total cost, including fees and any minimum commitment. Here is what Rewinding RX bundles in, and what it does not.
Clinician consult
Case review claimed as MD-only in the homepage hero
though the site's own FAQ separately lists nurse practitioners as part of its clinical network — a direct contradiction on the same page.
Bloodwork / labs
Not published
Follow-ups and dose changes
No cadence published
Human support
Not published
Injection supplies
Not published
Shipping
Not published
Pharmacy, labs and oversight
The pharmacy
Not individually named — only generic '503A/503B partner pharmacy' language.
Oversight
No cadence published.
Compounded peptides are not FDA-approved products, and a 503A pharmacy compounds for a named patient while a 503B outsourcing facility manufactures in batches under CGMP. Neither is a quality guarantee on its own — a named facility is simply a fact you can check, and an unnamed “partner pharmacy network” is not. Our guide to verifying a certificate of analysis covers what to ask for.
Where you can get it
All 50 states claimed, with physician state-licensing matching described.
The honest cons
The part they would rather you skipped
Rewinding RX's homepage hero states cases are reviewed by 'a fully licensed MD — never a physician assistant or nurse,' and — while its own FAQ on the identical page separately states its network includes 'physicians, nurse practitioners, dermatologists, and pharmacists,' a direct, same-page contradiction.
- Homepage claims cases are 'never' reviewed by a nurse; its own FAQ on the same page lists nurse practitioners in its network
- Legal entity name is inconsistent — 'LLC' on its About page, 'Ltd' in every footer
- No physical corporate address found anywhere on the site
- No specific compounding pharmacy named
Weigh these trade-offs against the costs, care and terms above. For questions to ask before enrolling, see our vendor red-flags guide.
Similar providers
- Rex MDA complete monthly treatment price is not establishedRead review →
- Revive MedsPrice unconfirmedRead review →
- Risen LabsPrice unconfirmedRead review →
- Revel RXSemaglutide is quoted at $89/monthRead review →
- Rivas Medical Weight LossSemaglutide $399/month and tirzepatide $599/monthRead review →
- Revel Health$199/mo ongoing for semaglutide, $249/mo for tirzepatideRead review →
Side by side: our semaglutide provider ranking · Every provider we review →
Read this before you buy
A provider comparison is half the decision. The other half is whether the compound does anything for you at all — and whether it is allowed where you compete. Growth-hormone secretagogues are banned in tested sport, year-round, and a prescription does not change that.
Provider offers and terms are based on Rewinding RX's public information. Other sources, where used, are identified in this review. Prices and terms change without notice — confirm on Rewinding RX's site before you buy. Provider names and logos on this page identify the company under review; their use does not imply endorsement, sponsorship or affiliation. This page is informational and not medical advice; compounded peptides are not FDA-approved, and growth-hormone secretagogues are banned in tested sport year-round. See our disclosure and editorial policy.